Currently, the treatment strategy for CLL involves several therapeutic options, including the use of Bcl-2 inhibitors such as venetoclax, addressing the overaccumulation of the Bcl-2 protein [33]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.